Thinking of joining a study?

Register your interest

Become a volunteer?

NCT03838926 | RECRUITING | Relapsed or Refractory Hematologic Malignancies

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Sponsor:

Vanda Pharmaceuticals

Brief Summary:

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Condition or disease

Relapsed or Refractory Hematologic Malignancies

Intervention/treatment

Trichostatin A

Phase

PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 42 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Actual Study Start Date : 2018-09-27
Estimated Primary Completion Date : 2025-12
Estimated Study Completion Date : 2025-12

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Subject is ≥ 18 years at the time of signing informed consent;
  • * Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;
  • * Presence of measurable or evaluable disease;
  • * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
  • * Contraceptives or other approved avoidance of pregnancy measures
Exclusion Criteria
  • * Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;
  • * Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
  • * Undergone major surgery ≤ 2 weeks prior to starting study drug;
  • * Evidence of mucosal or internal bleeding;
  • * Impaired cardiac function or conduction defect;
  • * Concurrent severe and/or uncontrolled medical conditions
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Location Details

NCT03838926

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

WITHDRAWN

United States, District of Columbia

Vanda Investigational Site

Washington, District of Columbia, United States, 20007

COMPLETED

United States, Indiana

Vanda Investigational Site

Lafayette, Indiana, United States, 47905

WITHDRAWN

United States, New Jersey

Vanda Investigational Site

Hackensack, New Jersey, United States, 07601

COMPLETED

United States, Washington

Vanda Investigational Site

Seattle, Washington, United States, 98109

RECRUITING

Poland,

Vanda Investigational Site

Biała Podlaska, Poland,

RECRUITING

Poland,

Vanda Investigational Site

Katowice, Poland,

RECRUITING

Poland,

Vanda Investigational Site

Cracow, Poland,

RECRUITING

Poland,

Vanda Investigational Site

Opole, Poland,

RECRUITING

Poland,

Vanda Investigational Site

Skorzewo, Poland,

RECRUITING

Poland,

Vanda Investigational Site

Warsaw, Poland,

RECRUITING

Poland,

Vanda Investigational Site

Wrocław, Poland,